C. Coronado Erdmann

442 total citations · 1 hit paper
12 papers, 339 citations indexed

About

C. Coronado Erdmann is a scholar working on Neurology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, C. Coronado Erdmann has authored 12 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Neurology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in C. Coronado Erdmann's work include Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (4 papers) and Attention Deficit Hyperactivity Disorder (2 papers). C. Coronado Erdmann is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (4 papers) and Attention Deficit Hyperactivity Disorder (2 papers). C. Coronado Erdmann collaborates with scholars based in Germany, United States and Japan. C. Coronado Erdmann's co-authors include Dirk Woitalla, Dirk Bremen, Siegfried Muhlack, Oliver Goetze, Thomas Müller, H. Przuntek, Wolfgang E. Schmidt, Tina Cascone, S. Meadows–Shropshire and Padma Sathyanarayana and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Movement Disorders.

In The Last Decade

C. Coronado Erdmann

11 papers receiving 337 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Coronado Erdmann Germany	9	210	94	64	53	49	12	339
Cataldo D’Amore Italy	8	185 0.9×	49 0.5×	11 0.2×	88 1.7×	87 1.8×	10	337
Dobri Baldaranov Germany	10	125 0.6×	37 0.4×	12 0.2×	25 0.5×	72 1.5×	18	330
S Hirai Japan	9	157 0.7×	44 0.5×	12 0.2×	14 0.3×	21 0.4×	23	315
R Boeri Italy	9	128 0.6×	36 0.4×	11 0.2×	30 0.6×	20 0.4×	28	302
K Takahashi Japan	9	93 0.4×	51 0.5×	46 0.7×	10 0.2×	19 0.4×	29	295
Hui Lian China	10	54 0.3×	81 0.9×	74 1.2×	8 0.2×	33 0.7×	22	358
Xiaodi Han China	10	137 0.7×	30 0.3×	13 0.2×	10 0.2×	103 2.1×	27	381
Hans Stimpel Denmark	8	226 1.1×	21 0.2×	15 0.2×	35 0.7×	118 2.4×	20	422
Marta Pirovano Italy	10	54 0.3×	36 0.4×	31 0.5×	96 1.8×	21 0.4×	26	283

Countries citing papers authored by C. Coronado Erdmann

Since Specialization

Citations

This map shows the geographic impact of C. Coronado Erdmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Coronado Erdmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Coronado Erdmann more than expected).

Fields of papers citing papers by C. Coronado Erdmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Coronado Erdmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Coronado Erdmann. The network helps show where C. Coronado Erdmann may publish in the future.

Co-authorship network of co-authors of C. Coronado Erdmann

This figure shows the co-authorship network connecting the top 25 collaborators of C. Coronado Erdmann. A scholar is included among the top collaborators of C. Coronado Erdmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Coronado Erdmann. C. Coronado Erdmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Provencio, Mariano, Mark M. Awad, Tina Cascone, et al.. (2024). LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study. Annals of Oncology. 35. S1239–S1240. 9 indexed citations

Awad, Mark M., Tina Cascone, Jonathan Spicer, et al.. (2024). LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study. ESMO Open. 9. 102985–102985. 2 indexed citations

Forde, Patrick M., Solange Peters, S. Meadows–Shropshire, et al.. (2024). PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. Journal of Thoracic Oncology. 19(10). S2–S2. 14 indexed citations

Provencio, Mariano, Mark M. Awad, Jie He, et al.. (2024). 121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC. ESMO Open. 9. 102700–102700.

Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →

Heine, Annkristin, et al.. (2013). Regression of Liver Metastases After Treatment With Oxaliplatin/Capecitabine and Development of a Progressive Multifocal Leukoencephalopathy in a Patient With Advanced Thymoma. Journal of Clinical Oncology. 31(12). e203–e205. 7 indexed citations

Erdmann, C. Coronado, et al.. (2009). Coinheritance of hereditary spherocytosis and reversibility of cirrhosis in a young female patient with hereditary hemochromatosis. European journal of medical research. 14(4). 182–182. 9 indexed citations

Müller, Thomas, Dirk Woitalla, Oliver Goetze, & C. Coronado Erdmann. (2008). Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease. Movement Disorders. 23(10). 1458–1461. 10 indexed citations

Müller, Thomas, C. Coronado Erdmann, Siegfried Muhlack, et al.. (2006). Entacapone improves complex movement performance in patients with Parkinson’s disease. Journal of Clinical Neuroscience. 14(5). 424–428. 11 indexed citations

10.

Müller, Thomas, C. Coronado Erdmann, Siegfried Muhlack, et al.. (2006). Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease. Journal of Neural Transmission. 113(10). 1441–1448. 45 indexed citations

11.

Erdmann, C. Coronado, Dirk Bremen, Wolfgang E. Schmidt, et al.. (2006). Impact of Gastric Emptying on Levodopa Pharmacokinetics in Parkinson Disease Patients. Clinical Neuropharmacology. 29(2). 61–67. 115 indexed citations

12.

Müller, Thomas, C. Coronado Erdmann, Siegfried Muhlack, et al.. (2005). Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels. Movement Disorders. 21(3). 332–336. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact